Research Article

Homood Alharbi, Mohammad Ahmad, Zhenhua Tian, Ruixue Yu, Yun Lun Li*

Therapeutic value of the metabolomic active neurotransmitter isorhynchophylline in the treatment of spontaneously hypertensive rats by regulating neurotransmitters

https://doi.org/10.1515/tnsci-2020-0185
received May 14, 2021; accepted September 3, 2021

Abstract: Hypertension is one of the most reported cardiovascular and cerebrovascular diseases with significantly high morbidity and mortality rates. This condition threatens the very existence of human beings. Numerous studies conducted earlier revealed the good therapeutic effect of isorhynchophylline on hypertension since the former regulates the metabolic disorders in neurotransmitters. However, the mechanism behind this action is yet to be deciphered. The current study followed the targeted metabolomics method to investigate the changes in the neurotransmitter level in the hippocampus of spontaneously hypertensive rats (SHRs) after the rats were treated with isorhynchophylline. The authors predicted the metabolic pathways involved in extensively modified neurotransmitters. Further, the expressions of metabolism-key enzymes in mRNA and protein levels were also determined. When treated with isorhynchophylline, it induced notably varying metabolomic profiles of the hippocampus in SHRs. Isorhynchophylline perturbed a total of seven extensively modified neurotransmitters as well as the primarily related pathways such as tyrosine and glutamate metabolism. An increase in the key metabolic enzymes such as DDC, MAO, COMT, TH, and DBH was observed in the SHR group, whereas their levels decreased after treatment with isorhynchophylline. The expression of GAD67 established cross-current validity. So, isorhynchophylline has been proved to have potential therapeutic value to treat hypertension via tyrosine and glutamate metabolism in the hippocampus. Further, the current study also opened new ventures to further investigate the working mechanism of isorhynchophylline in hypertension.

Keywords: isorhynchophylline, hippocampus, targeted metabolomics, hypertension, neurotransmitter

1 Introduction

Essential hypertension (EH) remains one such predominant cardiovascular disease that mostly affects middle-aged and elderly people globally. Further, EH is also deliberated as an important risk factor for cardiovascular and cerebrovascular diseases. WHO published a report in the year 2004, which stated that 7.5 million people succumb to death globally due to EH and it is also placed in the top ten position in terms of annual loss incurred upon leading a disability-adjusted life [1]. Being a complicated process, the pathogenesis of hypertension is a challenging process to accomplish and is inclusive of dysregulation of renin–angiotensin systems, immune system, and neurogenic system [2–4]. So, great attention is being paid to the molecular mechanism and treatment protocol of EH, in recent years. Numerous studies established that the central nervous system is a good regulator of blood pressure. The studies conducted earlier argued that the altered neurotransmitters and cytokines in the brain could relieve hypertension [5,6]. The brain has loads of neurotransmitters that act as base materials for the neuromodulation process [7]. So, it is critical to observe and investigate the changes that occur in neurotransmitter levels in vivo to understand the pathogenesis of hypertension and so pave the way for new targets for novel antihypertensive drugs.

Isorhynchophylline is traditionally used in Chinese medicine and is extracted from Uncaria sp. By modulating
the calcium ion channel, promoting autophagy, and through Aβ induced neurotoxicity, isorhynchophylline prevents the occurrence of amnesia and vascular dementia [8,9]. The compound exhibits antagonistic activity at the 5-HT2A receptor due to oxindole moiety configuration [8,10]. Further, when isorhynchophylline was applied in rats treated with Aβ25–35, it improved cognition by arresting beclin 1-mediated autophagy, induced by neuronal apoptosis, to aggravate the degradation of neuronal cell alpha-synuclein in primary cortical neurons, N2a, PC12 cells as well as SH-SYSY [10,11]. The studies conducted in recent times [7–10] established that isorhynchophylline performs as an antioxidant and anti-inflammatory agent. Further, it also exerts neuroprotective effects and regulates neurotransmitters. Although neurotransmitter metabolism is regulated by isorhynchophylline and the variations in neurotransmitter levels have a close relationship with hypertension pathogenesis, little or no research has been conducted so far upon antihypertensive mechanisms in isorhynchophylline-triggered neurotransmitter metabolism disorders.

Researchers aim to characterize the isorhynchophylline mechanism in the current study on the treatment of hypertension. Isorhynchophylline was administered to spontaneously hypertensive rats (SHRs) after which the hippocampus was extracted from the samples. This study used the UPLC-Q-extractive/MS-full mass scan technique, a standard qualitative and quantitative analysis method that can be used for endogenous neurotransmitters. The levels of different neurotransmitters in rats prior to and after the treatment were analyzed, followed by the investigation of coherent metabolic pathways.

2 Materials and methods

2.1 Chemicals and reagents

A total of seven neurotransmitters were procured from Sigma Aldrich (Milan, Italy) and were used as standards. The procured neurotransmitters were R grade standard l-phenylalanine, standard l-glutamate, standard l-tyrosine, epinephrine hydrochloride, homovanillic acid, l-glutamine, and γ-aminobutyric acid. Dr. Ehrenstorfer GmbH (Germany) provided the standard dopamine hydrochloride. Further, isochineine and isorhynchophylline of R Grade were procured from Sigma Aldrich (Banglore, India). SYBR Premix Ex TaqTM II (Thermo-fisher), PrimeScriptTM RT reagent Kit with gDNA Eraser (Perfect Real Time), and Trizol Total RNA Extraction Kit were procured from Thermo-Fisher (USA). R grade reagents indicate 99.5% purity.

2.2 Animal handling

In this study, six paired male Wistar-Kyoto (WKY) rats and 12 male-specific pathogen-free SHRs were maintained in the SPF animal laboratory. Each cage had 6 rats; the weight of SHRs was 176.76 ± 12.18 g and aged 8 weeks. The temperature of the laboratory was maintained at 22 ± 1°C, whereas the relative humidity was 52 ± 5%. After one week of acclimatization, random allotment of SHRs was performed for the SHR group (n = 6) as well as for the isorhynchophylline (IRN) group (n = 6). In the latter group, water solution was administered to the rats that were given isorhynchophylline monomer at 0.251 mg kg−1. The control group (6 WKY rats) that was normotensive and the SHR group were administered uniform amounts of physiological saline for four consecutive weeks with 6 days, a week. At the time of intervention, isorhynchophylline dosage was adjusted as per the weight of the rats, checked once a week. Before and after administration, the blood pressure of each rat was checked noninvasively from the tail artery, through the tail–tail method for 1–4 weeks. The protocol followed here was in line with the Guide for the Care and Use of Laboratory Animals. Further, appropriate approval was obtained from the Ethics Committee of the Institution. All the animals were anesthetized after 12 h of final administration using 1% pentobarbital sodium at a dose of 40 mg kg−1; the hippocampus tissues were extracted and stored at −80°C for further analysis.

Ethical approval: The research related to animals’ use has been complied with all the relevant national regulations and was reviewed and approved by the animal protection and use committee of Shandong University of Traditional Chinese Medicine.

2.3 Metabolomics based on LC-MS

The extracted hippocampus sample, measuring 15 mg, was cut into pieces and was blended with 5 μL of ascorbic acid (0.1 mg mL−1), 500 μL of acetonitrile–isopropanol–water (3:3:2, v/v/v), and 5 μL of IS solution. A high-throughput grinding machine was used to homogenize the mixture; then the mixture was centrifuged at 12,000 rpm at 4°C for 15 min. The resultant precipitate was re-dissolved using 400 μL of water–acetonitrile (96:4, v/v). After centrifugation, the supernatant was collected for LC/MS analysis. For the preparation of the working solution and internal standard, diazepam-d5 and vitamin C were dissolved in 1 mg mL−1 methanol:water blend at a
ratio of 1:1, v/v. This method was also followed to obtain
the reference standard solutions for eight neurotransmit-
ters (1 mg mL$^{-1}$). A standard curve was prepared for which
L-glutamine, L-tyrosine, L-phenylalanine, and dopamine
hydrochloride were diluted with IS and vitamin C at varying
concentrations in the range of 100–5,000 ng mL$^{-1}$. Likewise,
L-glutamate and γ-aminobutyric acid were also
diluted at varying concentrations in the range of
50–20,000 ng mL$^{-1}$. UPLC-QExactive-MS system was
used to quantify the neurotransmitters. The parameters
mentioned in the literature [14] were considered for
checking the accuracy of analysis and were validated
with quality control samples. Once the LC/MS analysis
was completed, principal component analysis (PCA) and
orthogonal partial least-squares discriminant analysis
(OPLS-DA) were performed for the metabolism datasets
of samples.

### 2.4 Verification of molecular biology

The hippocampus samples, collected from different groups,
were tested for determining the expression levels of rate-
limiting enzymes such as tyrosine hydroxylase (TH), cate-
chol-O-methyltransferase (COMT), dopamine β-hydroxylase
(DβH), dopa decarboxylase (DDC), glutamate decarboxylase
(GAD67), and monoamine oxidase (MAO) using RT-PCR.
These enzymes are generally involved in neurotransmitter
anabolism. The rest of the hippocampus samples were sub-
jected to homogenization in liquid nitrogen, whereas total
RNA was extracted after the application of Trizol reagents
(Bao Bioengineering, Dalian, China).

Once the concentration and purity of RNA were ver-
ified using a spectrophotometer, the first strand cDNAs
were subjected to reverse transcription with the help of a
reverse transcription kit (Promega, Madison, USA). Table 1
lists the oligos and primers utilized in this study (manu-
factured by Sangon Biotech, Shanghai, China). Based on
the instructions from the manufacturer, ELISA kits were
used to detect the protein contents of six related enzymes.
A total of nine biomarkers were used for pathway analysis in
MetaboAnalyst 3.0 software (https://www.metaboanalyst.ca)
to assess the extensively modified metabolic pathways, trig-
gered by the intervention of isorhynchophylline, in the hippo-
campus of SHRs.

### 2.5 Bioinformatics and statistical analysis

SPSS 17.0 software was used to conduct the statistical
analyses for the current study. All the experiments were
conducted in triplicates and the results are expressed as
mean ± standard deviation. Analysis of Variance (ANOVA)-
LSD was conducted to execute multiple comparisons if the
data are normally distributed; otherwise, the Kruskal–Wallis
test was applied after the Dunnett T3 test. If $P < 0.05$, then
the outcome was said to be statistically different.

SIMCA-P software (v 13.00, Umetrics, Umeå, Sweden)
was used to process the statistically significant neuro-
transmitter-targeted metabolomics data, saved in .xls format
for multivariate statistical analysis. Once the data were
scaled up, the orthogonal-partial least-squares (OPLS-DA)
method was used to distinguish the two groups, while the
parameters $R^2Y$ and $Q^2$ were used to assess the model’s
validity. Simultaneously, variable importance (VIP > 1) was used as a screening criterion to determine
the neurotransmitter metabolites that significantly dif-
ferentiated the groups.

### 3 Results

#### 3.1 Blood pressure level

The rats were checked for systolic and diastolic pressure
to determine the impact of isorhynchophylline on the
blood pressure of SHRs. Figure 1 shows that the SHR
group rats exhibited high systolic and diastolic pressure
compared to control group rats. When intervened with
isorhynchophylline, a significant decline was observed
in blood pressure (all $P < 0.05$) in SHR group rats.
Thus, the study results indicate that isorhynchophylline
inhibits hypertension to a significant level.

#### Table 1: The primer sequences of the target gene and internal reference

| Primer | Sequence |
|--------|----------|
| DDC    | 5′-CTAGGGTACACACGGAAA-3′ |
| COMT   | 5′-TGCGACTCTGGGTACGGC-3′ |
| MAO    | 5′-GGATTCTCCAGAAGA-3′ |
| GAD67  | 5′-CACATGTCGCTTCAGC-3′ |
| DβH    | 5′-GGAGGTGCGAGAAG-3′ |
| TH     | 5′-CTCAGAGAGTTGGC-3′ |

| Primer | Sequence |
|--------|----------|
| DDC    | 5′-CTAGGGTACACACGGAAA-3′ |
| COMT   | 5′-TGCGACTCTGGGTACGGC-3′ |
| MAO    | 5′-GGATTCTCCAGAAGA-3′ |
| GAD67  | 5′-CACATGTCGCTTCAGC-3′ |
| DβH    | 5′-GGAGGTGCGAGAAG-3′ |
| TH     | 5′-CTCAGAGAGTTGGC-3′ |
3.2 Targeted metabolomics analysis

Figure 2 shows the quantitative (ng mL\(^{-1}\)) and statistical results of eight neurotransmitters. In comparison with the control group, there was a significant increase observed in the expression levels of glutamine, dopamine, homovanillic acid, and glutamate in the SHR group. In parallel, the same group, i.e. SHR, exhibited a notable decline in γ-aminobutyric acid as well. There was a significant reversal observed in the expression levels of neurotransmitters in the SHR group after treating with isorhynchophylline; however, the same effect was not for γ-aminobutyric acid. They also showed a tendency to revert to normal levels. As per the indication from the unsupervised PCA model, every group had six specimens clustered together. This denotes that each group’s specimens possess similar characteristics. The OPLS-DA model was developed and portrayed to understand how groups were discriminated. From the clear cluster of WKY and SHR group samples, it can be understood that there existed a notably differential metabolism profile in the hippocampus tissues between SHRs and controls. Likewise, the clear demarcation between IRN and SHR groups infers that the metabolic changes observed in SHRs are the result induced by the isorhynchophylline treatment. For cross-validation, permutation tests were performed, whereas the model parameters such as \(R^2_X\) and \(R^2_Y\) were within the requirements. This outcome infers the presence of a reliable difference between the groups. As per variable importance in projection (VIP) values >1.0, 7 out of 8 substances in the hippocampus were regarded as potential metabolic biomarkers (Figures 3 and 4).

3.3 Molecular biology results

From the results, it can be observed that there were high DDC, MAO, COMT, TH, and DBH levels in the control and IRN groups compared to the SHR group. However, a vice versa trend was observed in the case of GAD67 alone (Figure 4). Similar results were exhibited by the IRN
group samples than the control group in terms of expression levels of all metabolism-key enzymes (Figure 5). Figure 6 shows similar protein expression patterns of metabolism-key enzymes.

4 Discussion

Various risk factors contribute to the occurrence of cardiovascular diseases among which hypertension is the most important one and has close ties with high mortality. Isorhynchophylline is an established compound known for its antihypertensive property, whereas its antihypertensive mechanism has a proven track record due to multichannel synergy. But, no studies have been conducted so far regarding its neuropathological mechanism. The current study followed the LC/MS-based metabolomics method to track the modifications in neurotransmitters when the hippocampus of SHRs was treated with isorhynchophylline. The results retrieved from quantitative analysis and OPLS-DA analysis of brain tissue samples from SHRs indicate that there exists a significant association between essential hypertension and the seven neurotransmitters including monoamine- and amino acid neurotransmitters. A disturbance was observed in both tyrosine and glutamate metabolism pathways. In this scenario, it is obvious that the expression profiles of six pathway-related key enzymes were altered in SHRs. However, when administered with isorhynchophylline, these alterations could be reversed. Thus, isorhynchophylline has been proved to protect SHRs from hypertension primarily through tyrosine and glutamate metabolism pathways.

In the current study, low content of tyrosine was found in the hippocampus of SHR group rats compared to WKY rats, although it was insignificant, and changes might be attributed to catecholamine disorder in the SHR group [12]. Being a rate-limiting enzyme, TH is held accountable for the biosynthesis of catecholamine. TH plays a key role in the first process of catecholamine biosynthesis, i.e., catalyzing the synthesis of levodopa, a biosynthetic precursor of catecholamine, through tyrosine [13]. When levodopa gets accumulated, it aggravates
the synthesis of catecholamines in addition to increased activities of DDC, DßH, MAO, and COMT [14]. In general, catecholamines enact an important role in increasing blood pressure since it damages the structure of neuronal cells through sympathetic activity [15]. When treated with isorhynchophylline, a significant decline was observed in catecholamine levels in hippocampus tissues of SHRs. This confirms the anti-hypertension effect of isorhynchophylline via regulating the biosynthesis of catecholamines. Glutamate and γ-GABA play crucial roles in blood pressure regulation by the maintenance of brain functions [16]. Glutamate, being an excitatory neurotransmitter, tends to activate RAAS when it is in high quantity and increases blood pressure [17]. GAD67 is generally involved in transforming glutamate to yaminobutyric acid. Being a suppressive neurotransmitter, γ-GABA is present in nerves and is sedative in nature when anti-neurons are hyperactive [15–17].

5 Conclusion

As per the current study outcomes, in comparison with control rats, a significant increase was observed in glutamate and glutamine levels when induced by hypertension and a decline was noticed in the γ-GABA level in the hippocampus of SHRs. However, when administered isorhynchophylline, these changes were reversed. An earlier study by Li et al. indicated the association of the antihypertensive effect of isorhynchophylline with tyrosine and glutamate metabolism in the hypothalamus, whereas in the present study we see isorhynchophylline treatment reduced blood pressure in SHRs through tyrosine and glutamate metabolism pathways in the hippocampus. Therefore, we can conclude that there are similar pathways from both brain regions involved in the antihypertensive effect of isorhynchophylline [18]; however, further work is required to ensure which part of the brain dominates the tyrosine and glutamate metabolism in association with the antihypertensive effect of isorhynchophylline. To conclude, the study outcomes reveal that tyrosine and glutamate metabolism is the main pathways, hindered by the intervention of isorhynchophylline, in the hippocampus region of the SHR group.

Acknowledgement: The authors are thankful to the Deanship of Scientific Research, College of Nursing, Research Centre at King Saud University for supporting this research.

Funding information: This study was supported by a foundation from the National Natural Science Foundation of China (grant no. 81774173), Youth Innovation and Technology Program for the Universities of Shandong Province (grant no. 2019KJM005), University Science and Technology Program of Shandong Province (grant no. J17KZ004), and 2019-2020 TCM Technology Development Plan Project of Shandong Province (grant no. 2019-0019, 2019-0021).

Author contributions: G.W. and Z.T. contributed to the study design, study conduct, and drafting of the manuscript. R.Y. and H.W. contributed to the data collection, data interpretation, and data analysis. H.J. and Y.L. revised the manuscript.

Conflict of interest: The authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Maeder MT, Schoch OD, Rickli H. A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:85.
[2] Perrotta M, Carnevale D. Brain areas involved in modulating the immune response participating to hypertension and its target organ damage. Antioxid Redox Signal. 2021 Jul 16.
[3] Calvillo L, Gironacci MM, Crotti L, Meroni PL, Parati G. Neuroimmune crosstalk in the pathophysiology of hypertension. Nat Rev Cardiol. 2019 Aug;16(8):476–90.
[4] Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res. 2018;11:179.
[5] Leopold AV, Shcherbakova DM, Verkhusha VV. Fluorescent biosensors for neurotransmission and neuromodulation: engineering and applications. Front Cell Neurosci. 2019 Oct 23;13:474.
[6] Geetha RG, Ramachandran S. Recent advances in the anti-inflammatory activity of plant-derived alkaloid rhynchophylline in neurological and cardiovascular diseases. Pharmaceutics. 2021 Aug;13(8):1170.
[7] Shi JS, Yu JX, Chen XP, Xu RX. Pharmacological actions of uncaria alkaloids, rhynchophylline and isorhynchophylline. Acta Pharmacol Sin. 2003 Feb 1;24(2):97–101.
[8] Matsumoto K, Morishige R, Murakami Y, Tohda M, Takayama H, Sakakibara I, et al. Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies. Eur J Pharmacol. 2005 Jul 11;517(3):191–9.
[9] Yang XP, Liu W, Sun X. Investigation of rhynchphylla total alkaloids stability and the quantitative determination of
rhyncho-phylline and isorhynchophylline. Pract J Med Pharm. 2012;3.

[10] Zhang F, Sun AS, Yu LM, Wu Q, Gong QH. Effects of isorhynchophylline on angiotensin II-induced proliferation in rat vascular smooth muscle cells. J Pharm Pharmacol. 2008 Dec;60(12):1673–8.

[11] Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, et al. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 2012 Jan 1;8(1):98–108.

[12] Xiong X, Yang X, Liu Y, Zhang Y, Wang P, Wang J. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertension Res. 2013 Jul;36(7):570–9.

[13] Rao F, Zhang L, Wessel J, Zhang K, Wen G, Kennedy BP, et al. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation. 2007 Aug 28;116(9):993–1006.

[14] Gillbro JM, Marles LK, Hibberts NA, Schallreuter KU. Autocrine catecholamine biosynthesis and the β2-adrenoceptor signal promote pigmentation in human epidermal melanocytes. J Investig Dermatol. 2004 Aug 1;123(2):346–53.

[15] Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord. 2014 Dec;29(14):171–9.

[16] Yu R, Yang W, Qi D, Gong L, Li C, Li Y, et al. Targeted neurotransmitter metabolomics profiling of oleanolic acid in the treatment of spontaneously hypertensive rats. RSC Adv. 2019;9(40):23276–88.

[17] Sun LH, Fan YY, Wang X, Zheng HB. Pharmacodynamic elucidation of glutamate & dopamine in ketamine-induced anaesthesia. Chem-Biol Interact. 2020 Aug 25;327:109164.

[18] Li Y, Yu R, Zhang D, Yang W, Hou Q, Li Y, et al. Deciphering the mechanism of the anti-hypertensive effect of isorhynchophylline by targeting neurotransmitters metabolism of hypothalamus in spontaneously hypertensive rats. ACS Chem Neurosci. 2020 May 1;11(11):1563–72.